title: Transgenic mice expressing a mutant form of loricrin reveal the molecular basis of the skin diseases, Vohwinkel syndrome and progressive symmetric erythrokeratoderma.
abstract: Mutations in the cornified cell envelope protein loricrin have been reported recently in some patients with Vohwinkel syndrome (VS) and progressive symmetric erythrokeratoderma (PSEK). To establish a causative relationship between loricrin mutations and these diseases, we have generated transgenic mice expressing a COOH-terminal truncated form of loricrin that is similar to the protein expressed in VS and PSEK patients. At birth, transgenic mice (ML.VS) exhibited erythrokeratoderma with an epidermal barrier dysfunction. 4 d after birth, high-expressing transgenic animals showed a generalized scaling of the skin, as well as a constricting band encircling the tail and, by day 7, a thickening of the footpads. Histologically, ML. VS transgenic mice also showed retention of nuclei in the stratum corneum, a characteristic feature of VS and PSEK. Immunofluorescence and immunoelectron microscopy showed the mutant loricrin protein in the nucleus and cytoplasm of epidermal keratinocytes, but did not detect the protein in the cornified cell envelope. Transfection experiments indicated that the COOH-terminal domain of the mutant loricrin contains a nuclear localization signal. To determine whether the ML.VS phenotype resulted from dominant-negative interference of the transgene with endogenous loricrin, we mated the ML.VS transgenics with loricrin knockout mice. A severe phenotype was observed in mice that lacked expression of wild-type loricrin. Since loricrin knockout mice are largely asymptomatic (Koch, P.K., P. A. de Viragh, E. Scharer, D. Bundman, M.A. Longley, J. Bickenbach, Y. Kawachi, Y. Suga, Z. Zhou, M. Huber, et al., J. Cell Biol. 151:389-400, this issue), this phenotype may be attributed to expression of the mutant form of loricrin. Thus, deposition of the mutant protein in the nucleus appears to interfere with late stages of epidermal differentiation, resulting in a VS-like phenotype.
authors.affiliation: Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Suga
authors.forename: M
authors.initials: M
authors.lastname: Jarnik
authors.forename: P S
authors.initials: PS
authors.lastname: Attar
authors.forename: M A
authors.initials: MA
authors.lastname: Longley
authors.forename: D
authors.initials: D
authors.lastname: Bundman
authors.forename: A C
authors.initials: AC
authors.lastname: Steven
authors.forename: P J
authors.initials: PJ
authors.lastname: Koch
authors.forename: D R
authors.initials: DR
authors.lastname: Roop
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002451:Cell Compartmentation; D002462:Cell Membrane / Q000737:chemistry; D003638:Deafness / Q000209:etiology* / Q000235:genetics; D016368:Frameshift Mutation; D007642:Keratosis / Q000209:etiology* / Q000235:genetics; D008565:Membrane Proteins / Q000235:genetics*; D051379:Mice; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D019913:Nuclear Localization Signals; D010641:Phenotype; D021381:Protein Transport; D012867:Skin / Q000473:pathology; D012879:Skin Physiological Phenomena / Q000235:genetics; D013577:Syndrome
chemical_list: D008565:Membrane Proteins; D019913:Nuclear Localization Signals; C064554:loricrin